-- 周四，生物燃料原料期货价格涨跌互现，其中豆油期货价格再次触及合约高点，而大豆期货价格则从早盘低点反弹，远期合约价格小幅上涨。 芝加哥期货交易所（CBOT）7月大豆期货合约周四收跌0.13%，报每蒲式耳11.95美元；CBOT 7月豆油期货合约收涨0.57%，报每磅74.54美分。 周三，纽约商品交易所（Nymex）6月乙醇期货合约收涨3.39%，报每加仑2.06美元。 DTN分析师雷特·蒙哥马利表示，小麦期货市场的避险情绪蔓延至其他农产品期货市场。 蒙哥马利在每日报告中指出：“玉米市场疲软的局面蔓延开来，而大豆市场则更具韧性，交易员们仍愿意等待5月份特朗普/习近平峰会的结果，然后再对长期价格走势做出判断。” 美国众议院通过了一项“精简版”农业法案。原本，E15农村国内能源委员会提出的全年全国性E15燃料提案也应同时进行投票表决。 经过持续的谈判，E15提案的投票将于5月13日国会休会后进行。 周四，美国农业部报告称，截至4月23日当周，2025/26年度大豆出口销量增加950万蒲式耳（约25.81万吨），而2026/27年度销量增加10万蒲式耳（约3000吨）。 上周出口量为 2240 万蒲式耳，高于美国农业部为实现 2025/26 年 15.4 亿蒲式耳的出口预估目标所需的每周 1750 万蒲式耳。目前，2025/26 年大豆出口承诺总量为 14.25 亿蒲式耳，比一年前下降了 18%。
Related Articles
Research
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
$BIO
Asia
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
$ASX:RMD
Research
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.
$GDDY